# Optobionics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/optobionics

- Industry: Medical Devices & Equipment
- Headquarters: Glen Ellyn, US
- Website: optobionics.com
- Total disclosed funding: $5M
- Latest round: Series D (Jun 12, 2006)
- Investors on record: 5

## About

Optobionics is a biotechnology firm that focuses on developing innovative ophthalmic solutions, particularly for patients suffering from vision loss due to retinal diseases.Optobionics develops advanced solutions for vision restoration, notably the Artificial Silicon Retina (ASR). The company is based in Glen Ellyn, US. Founded by a team of experts in retinal technology, Optobionics completed its latest funding round, a Series D, on June 12, 2006, raising USD 5.00 mn from investors including ARCH Venture Partners and Medtronic, bringing the total amount raised to USD 5.00 mn. The current valuation of the company is USD 110.97 mn.Optobionics specializes in advanced ophthalmic solutions, particularly the Artificial Silicon Retina (ASR) implant, designed to address vision loss caused by conditions such as Retinitis Pigmentosa. The ASR mimics natural processes of the retina, converting light into electrical signals that stimulate functional cells in the retina. Targeted toward patients with retinal degenerative disorders, the ASR represents a notable advancement in retinal prosthetics, primarily serving the U.S. market with potential for expansion into international markets where similar conditions exist.Revenue generation for Optobionics is primarily derived from the sale of ASR implants marketed directly to healthcare facilities and clinics treating retinal disorders. The B2B transaction structure involves healthcare providers purchasing the implants, complemented by partnerships with medical institutions for ongoing research and development. Revenue also includes potential follow-up services and patient support programs, ensuring a sustainable revenue flow while contributing to visual health enhancement.In July 2006, Optobionics secured USD 5.00 mn in Series D financing from returning investors, which will be used to enhance product development and market presence. The company plans to explore the introduction of new ophthalmic products aimed at improving vision restoration. Additionally, Optobionics is considering expansion into international markets by 2007, targeting regions with a high prevalence of retinal diseases to broaden its impact on eye health.

## Funding rounds

- Series D, Jun 12, 2006, $5M — Advanced Technology Ventures, ARCH Venture Partners, Polaris Partners, Medtronic, CIBA Vision Corporation

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series D
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series D
- Medtronic — Series D
- CIBA Vision Corporation — Series D